|
WO2021079315A1
|
|
Steerable needles
|
|
US2021115129A1
|
|
Safe and Effective Method of Treating Ulcerative Colitis with Anti-IL12/IL23 Antibody
|
|
WO2021076855A1
|
|
Dynamic monosaccharide control processes
|
|
WO2021070132A1
|
|
Bi-aryl dihydroorotate dehydrogenase inhibitors
|
|
WO2021072169A1
|
|
Materials and methods for mass spectrometric protein analysis
|
|
WO2021064671A1
|
|
Methods for producing biotherapeutics with increased stability by sequence optimization
|
|
WO2021067191A1
|
|
Compositions and methods for an il-17 target engagement assay with small molecule modulators
|
|
WO2021067195A1
|
|
Compositions and methods for an il-17 target engagement assay with large molecule modulators
|
|
WO2021055894A1
|
|
Materials and methods for differential characterization of molecular conjugates and conjugation
|
|
WO2021059075A1
|
|
Anti-ceacam antibodies and uses thereof
|
|
US2020392242A1
|
|
Combination Therapies Comprising Daratumumab, Bortezomib, Thalidomide and Dexamethasone and Their Uses
|
|
WO2021038524A1
|
|
B-cell maturation complex car t construct and primers
|
|
US2020405854A1
|
|
Combination Therapies Comprising Daratumumab, Bortezomib, Thalidomide and Dexamethasone and Their Uses
|
|
WO2021038490A1
|
|
Substituted urea dihydroorotate dehydrogenase inhibitors
|
|
WO2021038474A1
|
|
Tissue anchor and related methods
|
|
WO2021041486A1
|
|
Chimeric antigen receptor system and uses thereof
|
|
US2020397896A1
|
|
Combination Therapies Comprising Daratumumab, Bortezomib, Thalidomide and Dexamethasone and Their Uses
|
|
US2021047435A1
|
|
Materials and methods for improved single chain variable fragments
|
|
WO2021030657A1
|
|
Materials and methods for improved single chain variable fragments
|
|
US2021047423A1
|
|
Therapeutic immune cells with improved function and methods for making the same
|
